These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 18416992)
21. Regulating the safety of pharmaceuticals: the FDA, preemption, and the public's health. Gostin LO JAMA; 2009 May; 301(19):2036-7. PubMed ID: 19454642 [No Abstract] [Full Text] [Related]
23. FDA prohibits extralabel use of two drug classes. J Am Vet Med Assoc; 1997 Aug; 211(3):269. PubMed ID: 9262656 [No Abstract] [Full Text] [Related]
24. FDA perspectives on supplement use by patients on antithrombotic therapy: dietary supplement regulatory overview. Woo JJ Thromb Res; 2005; 117(1-2):193-6; discussion 201-7. PubMed ID: 16253311 [No Abstract] [Full Text] [Related]
25. Pharmaceuticals and medical devices: FDA oversight. Issue brief. Thomson Reuters/West Issue Brief Health Policy Track Serv; 2011 Jan; ():1-39. PubMed ID: 21374841 [No Abstract] [Full Text] [Related]
26. How the FDA can overturn Wyeth v. Levine. Gostanian A Am J Law Med; 2010; 36(1):248-68. PubMed ID: 20481407 [TBL] [Abstract][Full Text] [Related]
27. ACNP/SNM work to amend FDA reform bill. American College of Nuclear Physicians/Society of Nuclear Medicine. Nichols D J Nucl Med; 1997 Sep; 38(9):39N-40N. PubMed ID: 9293781 [No Abstract] [Full Text] [Related]
28. Deterring inefficient pharmaceutical litigation: an economic rationale for the FDA regulatory compliance defense. Viscusi WK; Rowland SR; Dorfman HL; Walsh CJ Spec Law Dig Health Care Law; 1996 Mar; (205):9-52. PubMed ID: 10156421 [No Abstract] [Full Text] [Related]
29. Modernizing the FDA: an incremental revolution. Merrill RA Health Aff (Millwood); 1999; 18(2):96-111. PubMed ID: 10091437 [TBL] [Abstract][Full Text] [Related]
30. FDA to require pediatric studies for drugs commonly used in children. Miller JL Am J Health Syst Pharm; 1999 Feb; 56(3):203. PubMed ID: 10030499 [No Abstract] [Full Text] [Related]
31. Reimbursement for unlabeled medication use. Brushwood DB Am J Health Syst Pharm; 1999 Feb; 56(3):257-9. PubMed ID: 10030514 [No Abstract] [Full Text] [Related]
32. Greater and lesser powers of tort reform: the primary jurisdiction doctrine and state-law claims concerning FDA-approved products. Struve CT Cornell Law Rev; 2008 Jul; 93(5):1039-74. PubMed ID: 18618970 [No Abstract] [Full Text] [Related]
33. The use of Food and Drug Administration--approved medications for unlabeled (off-label) uses. The legal and ethical implications. Torres A Arch Dermatol; 1994 Jan; 130(1):32-6. PubMed ID: 8285737 [TBL] [Abstract][Full Text] [Related]
34. The Food and Drug Administration's paternalism. Somberg JC Am J Ther; 2010; 17(6):533-4. PubMed ID: 21060255 [No Abstract] [Full Text] [Related]
35. Tricky FDA debate: should a risky drug be approved again? Mathews AW; Westphal SP Wall St J (East Ed); 2006 Feb; ():B1, B4. PubMed ID: 16528879 [No Abstract] [Full Text] [Related]
36. Inappropriate advertising of dietary supplements. Taylor H N Engl J Med; 2003 May; 348(22):2255-6; author reply 2255-6. PubMed ID: 12773657 [No Abstract] [Full Text] [Related]
37. Insights and issues from FDA Advisory Committee meetings on abuse-deterrent opioids. Miller CJ; Dart RC; Katz NP; Webster LR J Opioid Manag; 2017; 13(6):379-389. PubMed ID: 29308585 [TBL] [Abstract][Full Text] [Related]